[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oct-angiography\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oct-angiography":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100650522","chorioretinal-imaging-vascular-biomarkers-and-ultra-trail-a-pilot-study-100650522",false,"NCT07748936","Chorioretinal Imaging, Vascular Biomarkers, and Ultra-Trail: A Pilot Study","UTMA-RETINA","Inclusion Criteria:\n\n* Participant who has given free, informed, and verbal consent\n* Participant of legal age\n* Participant registered for the UTMA 100 km solo ultra-trail race (for the \"ultra-trail\" group)\n* Active subject not exposed to intense physical exertion (\\>6 hours of exercise) within the 7 days prior to the enrollment visit (for the \"active control\" group)\n* Participant with an estimated physical activity level of 4-6 hours per week (for the \"active control\" group)\n* Participant agreeing to undergo ophthalmological examinations on the same schedule as the ultra-trail group (for the \"active control\" group)\n\nExclusion Criteria:\n\n* Myopia \\> 6 diopters\n* Type 1 or Type 2 diabetes\n* Protected individuals: Minors, individuals under legal protection (guardianship, conservatorship, court order), individuals unable to give informed consent\n* Individuals not enrolled in a social security program\n* Pregnant or breastfeeding women\n* Participants with a systemic or inflammatory vascular condition and cardiovascular risk\n* Participants with an ocular condition or ophthalmological history likely to impair retinal\u002Fchoroidal microcirculation or the quality of imaging (vascular and degenerative macular conditions, cataracts)\n* Participants being treated with vasoconstrictors\n* Tobacco use within 4 hours prior to enrollment\n* Caffeine consumption within 1 hour prior to enrollment",true,"ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Retinal and choroidal microcirculation is a relevant biomarker of systemic vascular health and lies at the heart of eye-heart interactions. Noninvasive retinal imaging, particularly OCT angiography (OCT-A), now makes it possible to examine retinal and choroidal microvascularization in vivo and to study its relationship with systemic cardiovascular and neurovascular mechanisms.\n\nUltra-endurance activities, such as ultra-trail races, induce significant systemic hemodynamic changes, including dehydration, variations in perfusion pressure, prolonged sympathetic activation, and redistribution of blood flow. These physiological adaptations could lead to acute and reversible changes in retinal and choroidal vascular parameters as measured by retinophotography and OCT angiography.\n\nSeveral studies suggest that intense physical exercise may be accompanied by significant changes in retinal and choroidal microvascular perfusion. In particular, a significant decrease in the vascular density of the superficial retinal plexus has been observed following intense exercise in a healthy population, suggesting a transient change in retinal microcirculation. Similarly, following a marathon, a decrease in the retinal vascular density index (RVDI) has been reported, likely related to exercise-induced vasoconstriction and a transient reduction in retinal blood flow. This decrease may also be exacerbated by the drop in systemic blood pressure and the relative dehydration observed after the race. More broadly, intense endurance exercise is accompanied by cardiovascular and neurohormonal adaptations, particularly through activation of the renin-angiotensin-aldosterone system, which may modulate ocular perfusion. Scott et al. demonstrated, following a 160-km ultramarathon, significant alterations in left ventricular function and a major elevation in NT-pro-BNP, indicating systemic cardiovascular stress that was markedly greater than that observed after a standard marathon. Furthermore, a multi-omics study conducted during the Ultra-Trail du Mont-Blanc (171 km) revealed systemic oxidative stress, marked inflammation with elevated IL-6 levels, and profound metabolic changes affecting red blood cells-mechanisms recognized as being involved in microvascular dysfunction. However, these variations primarily reflect functional changes in perfusion related to hemodynamic status and autonomic tone, rather than true structural microvascular remodeling or angiogenesis. Metrics derived from OCT angiography, such as vascular density or perfusion density, are in fact sensitive to systemic variations in circulating volume, perfusion pressure, and the quality of the acquired signal.\n\nIn this context, the effects of ultra-endurance exercise on the eye remain poorly characterized. Research in this area is necessary to better understand the acute physiological adaptations of ocular microcirculation and to highlight the value of retinal imaging as a tool for cardiovascular research and prevention within an integrated eye-heart approach.",[27,28,29,30],"OCT Angiography","Retinal Microcirculation","Choroidal Microcirculation","Physical Exercion","NOT_YET_RECRUITING","2026-07-31",{"date":34,"type":35},"2026-08-06","ACTUAL",{"date":37,"type":21},"2026-10",{"date":39,"type":21},"2027-02",{"name":41,"class":42},"Centre Hospitalier Universitaire Dijon","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":68,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100617275","optimal-strategy-to-correct-stent-underexpansion-in-resistant-lesions-100617275","NCT07316504","Optimal Strategy to Correct Stent underexpAnsion in Resistant Lesions","OSCAR","Inclusion criteria :\n\n* Patient who have undergone coronary angiography with ISR, defined as ≥50% reduction of the diameter of the intrastent lumen occurring ≥ 6 months after stent implantation\n* And with a suspicion of stent under-expansion on angiography, possibly assisted by a stent enhancement technique\n* The reference diameter of the target vessel must be ≥2.5 mm and ≤5.0 mm.\n* Coronary flow must be TIMI 3\n* Ability to cross the lesion with the OCT catheter (possibly after predilatation with a balloon up to 2 mm)\n* Patient affiliated to the French National Health Insurance\n\nExclusion criteria :\n\n* Heart failure with NYHA III or IV (or cardiogenic shock)\n* LVEF \\\u003C20%\n* Chronic renal failure with clearance \\\u003C30mL\u002Fmn according to CKD\n* Pregnant or breast-feeding women\n* Patient with a condition\u002Fcomorbidity that could reduce compliance with the protocol, including pre-specified study follow-up\n* Patient participating in another ongoing medical study evaluating a pharmacological or biological agent or medical device, unless authorized by the concomitant protocol.\n* Patient unable to tolerate double antiaggregation (i.e., aspirin and clopidogrel or prasugrel or ticagrelor) for at least 6 months.\n* Possible or defined thrombus (by angiography or endovascular imaging) in the target vessel.",{"count":52,"type":21},80,[24],"Percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) accounts for 5-10% of PCI. ISR may be linked to mechanical complications mainly under-expansion (UE), neointimal hyperplasia and\u002For neoatherosclerosis. International guidelines recommends non-compliant and very-high-pressure balloons, which lead to sub-optimal angiographic and clinical results. Recently, observational studies have suggested the feasibility and safety of intravascular lithotripsy (IVL) in UE treatment. There are no prospective randomised controlled studies comparing intravascular lithotripsy with balloons in ISR with UE.",[56,57,58,59,60,61,27,62,63,64,65,66,67],"Coronary Angioplasty","Restenosis","Lithotripsy","Restenosis of Coronary Artery Stent","Angioplasty, Transluminal, Percutaneous Coronary","Percutaneous Coronary Intervention (PCI)","Optical Coherence Tomography (OCT)","Intravascular Lithotripsy; Rotational Atherectomy; OFDI","Intravascular Lithotripsy","Coronary Artery Disease","Coronary Artery Disease (CAD)","Coronary Stent Restenosis",[69,70,71,72,73,74,75],"restenosis","underexpansion","intrastent restenosis","randomized clinical trial","intravascular lithotripsy","baloon PCI","Percutaneous coronary intervention","RECRUITING","2025-12-18",{"date":79,"type":35},"2026-01-05",{"date":81,"type":35},"2025-10-22",{"date":83,"type":21},"2031-09",{"name":85,"class":42},"University Hospital, Clermont-Ferrand",2,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":108,"locationsCount":43},"100595770","coronary-evaluation-and-guided-lesion-exploration-using-photon-counting-ct-and-intracoronary-imaging-techniques-100595770","NCT07036770","Coronary Evaluation And Guided Lesion Exploration Using Photon-counting CT and Intracoronary Imaging Techniques","C-EAGLE","Inclusion criteria:\n\nParticipants eligible for inclusion in this study must meet all of the following criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n2. At least 18 years of age at the time of signing the Informed Consent Form (ICF).\n3. Patients presenting with suspected acute coronary syndrome (UA or NSTEMI) or chronic coronary syndrome (stable angina or silent ischemia).\n\nExclusion criteria:\n\nParticipants eligible for this study must not meet any of the following criteria:\n\n1. Patients presenting with STEMI.\n2. Haemodynamically unstable patients.\n3. Unstable ventricular arrhythmias.\n4. Killip class III-IV heart failure.\n5. Creatinine clearance \\\u003C30 ml\u002Fmin\u002F1.73 m2 (as calculated by CKD-EPI formula 2009 for estimated GFR) and not on dialysis. Note: patients dependent on long-term dialysis are eligible for enrolment irrespective of their creatinine clearance levels.\n6. Severe coronary vessel tortuosity.\n7. Subject has known hypersensitivity to radiocontrast dye or that cannot be adequately pre-medicated.\n8. Female who is pregnant or breast-feeding.",{"count":95,"type":21},100,"OBSERVATIONAL","This study evaluates the diagnostic accuracy and limitations of photon-counting computed tomography (PCCT) in characterizing coronary plaque, with comparisons to optical coherence tomography (OCT) and intravascular ultrasound (IVUS). The objective is to assess whether cardiac ultra-high resolution (UHR) PCCT -with its improved spatial resolution and superior soft tissue contrast relative to conventional CT- can serve as a reliable, non-invasive alternative for coronary plaque assessment and support clinical decision-making. A total of 100 patients with either acute or chronic coronary syndrome will be enrolled, including 40 individuals with suspected in-stent restenosis and 10 patients one year post-percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). All participants will undergo invasive coronary angiography based on current European Society of Cardiology guidelines. Cardiac PCCT imaging will be conducted shortly before the angiographic procedure, accompanied by invasive OCT evaluation. Additionally, a subgroup of 10 patients will undergo both OCT and IVUS, allowing for direct comparison across imaging modalities. OCT, regarded as the gold standard for plaque characterization, offers near-histological resolution for identifying plaque features, while IVUS is particularly effective in evaluating plaque burden and volume.",[65,27,99],"CT",[101],"PCCT","2025-06-16",{"date":104,"type":35},"2025-06-25",{"date":102,"type":21},{"date":107,"type":21},"2027-05-31",{"name":109,"class":42},"Universitaire Ziekenhuizen KU Leuven"]